首页> 外文OA文献 >Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

【2h】

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

机译：用屈服in或第二代ALK抑制剂治疗的ALK阳性肺癌患者的结果：一种单杆机构经验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Elisa De Carlo; Maria Chiara Del Savio; Jerry Polesel; Valentina Da Ros; Eleonora Berto; Sandra Santarossa; Emanuela Chimienti; Lucia Fratino; Alessandra Bearz;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib [J] . BrosnanE.M., WeickhardtA.J., LuX., Cancer: A Journal of the American Cancer Society . 2014,第5期

机译：用ALK抑制剂克唑替尼治疗的ALK阳性非小细胞肺癌患者的药物诱导的估计的肾小球滤过率降低
2. Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer. [J] . Fiona Blackhall, Dong-Wan Kim, Benjamin Besse, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第11期

机译：患者报告的概况1007中的生活质量和生活质量：在先前治疗的ALK阳性晚期非小细胞肺癌患者中，CRIZOTINIB的随机试验。
3. Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer. [J] . Fiona Blackhall, Dong-Wan Kim, Benjamin Besse, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2014,第11期

机译：患者报告的结果和生活质量数据（PROFILE 1007）：在先前治疗的ALK阳性晚期非小细胞肺癌患者中，克唑替尼与化学治疗的随机对照试验。
4. High throughput multiplexed phosphoproteomics identifies drivers of resistance to ALK inhibitor treatment in lung cancer [C] . Amanda L. Edwards, Luc Friboulet, Rosa Frias, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：高通量复用磷蛋白酶鉴定肺癌抗华抗抑制剂治疗的驱动因素
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience [O] . Elisa De Carlo, Maria Chiara Del Savio, Jerry Polesel, 2018

机译：克唑替尼或第二代ALK抑制剂治疗ALK阳性肺癌患者的结果：单机构经验
7. Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer [O] . Ou Sai-Hong Ignatius, Bazhenova Lyudmila, Camidge D. Ross, 2010

机译：非小细胞肺癌ALK易位患者对ALK抑制剂（Crizotinib，PF02341066）的快速而戏剧性的影像学和临床反应

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

著录项

引文网络

相似文献

相关主题

期刊订阅